Kisspeptin-10 vs PT-141 (Bremelanotide)
A side-by-side research comparison of Kisspeptin-10 and PT-141 (Bremelanotide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Kisspeptin-10 | PT-141 (Bremelanotide) |
|---|---|---|
| Full name | Kisspeptin-10 (Metastin 45-54) | Bremelanotide (PT-141 / Vyleesi) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound | FDA Approved |
| Mechanism | Binds KISS1R on GnRH neurons, stimulating GnRH pulsatile release for LH/FSH secretion. Also enhances limbic sexual arousal circuits. | MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms. |
| Molecular weight | 1,302 Da | 1,025 Da |
| Half-life | 4-6 min (IV) / 20-30 min (SubQ) | 2.7 hours |
| Bioavailability | High (IV/SubQ) | High (SubQ) |
| Typical dose | 1-10 nmol/kg | 1.75 mg |
| Frequency | Single dose or daily | As needed, ~45 min before activity |
| Route | IV or Subcutaneous | Subcutaneous injection |
Kisspeptin-10 reported benefits
- Stimulates GnRH naturally
- Increases LH and testosterone
- Enhances sexual arousal (fMRI data)
- Potential fertility aid
- HPG axis diagnostic tool
PT-141 (Bremelanotide) reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
Related comparisons
Research and educational reference only. Not medical advice.